program｜The 94th Annual Meeting of the Japanese Pharmacological Society

Company-Organized Symposium

Current status of drug development for hematological malignancies

2-S15-19:0010:30 Research and clinical development of quizartinib (VANFLYTA) as a therapy for the patients with acute myeloid leukemia Takahiko Seki Daiichi Sankyo Co., Ltd., Oncology Res Labs II

2-S15-29:0010:30 Current Therapeutic Strategies and New Drug Development in Multiple Myeloma Kiyoshi Okazuka

2-S15-39:0010:30 Current status and challenge of CAR-T therapy for malignant lymphoma Yoneda Tomohiro Novartis pharma K.K.

Symposium21

New horizon for clinical application and drug discovery from basic science

2-S21-110:3012:00 Phosphorylation of Smurf2, a novel therapeutic target, regulates stemness and tumorigenicity of glioma stem cells Takashi Iezaki, Eiichi Hinoi Laboratory of Pharmacology, Department of Bioactive Molecules, Gifu Pharmaceutical University

2-S21-210:3012:00 Development of liver organoid culture from NASH mouse model and the application to drug discovery Tatsuya Usui Tokyo University of Agriculture and Technology

2-S21-310:3012:00 Feasibility of canstatin, a cleaved product of type IV collagen α2 chain, as a novel biomarker and therapeutic target in cardiac diseases Muneyoshi Okada Lab. Vet. Pharmacol., Sch. Vet. Med., Kitasato Univ.

2-S21-410:3012:00 Therapeutic application utilizing the anti-inflammatory effect of IL-19 Yasu-Taka Azuma Lab. Vet. Pharm., Osaka Pref. Univ.

Oral Sessions

Cancer, Chemotherapy, Antibody Therapy (2)

2-O-D1-115:3015:42 Establishment of a culture method of the feline mammary tumor organoid Matsui Riho, Tatsuya Usui Lab. Veterinary Pharamcology, Tokyo University of Agriculture and Technology

2-O-D1-215:4215:54 Effects of prolyl hydroxylase inhibitors on tumor blood vessels in tumor mouse model. Shinji Matsunaga¹, Kazuyuki Yamaguchi^1,2, Kentaro Tokudome¹, Takehiro Yamaguchi¹, Shuhei Tomita¹ ¹Dept. Pharmacol., Grad. Sch. Med., Osaka City Univ., ²Dept. Uro., Grad. Sch. Med., Osaka City Univ.

2-O-D1-315:5416:06 Differentiation-inducing factor-1 attenuated cellular motility of BRAF^V600E　mutation bearing malignant melanoma cells via altering mesenchymal features Masaki Arioka, Shiori Taura, Fumi Tetsuo, Momoko Kubo, Toshiyuki Sasaguri Dept. Clin. Pharmacol. Kyushu Univ.

2-O-D1-416:0616:18 Development of a monoclonal antibody for CD44-expressing oral cancers Junko Takei^1,2, Mika K. Kaneko¹, Tomokazu Ohishi³, Teizo Asano¹, Manabu Kawada³, Hiroyuki Harada², Yukinari Kato^1,4 ¹Dept. Antibody Drug Development, Tohoku University Grad. Sch. of Med., ²Dept. Oral & Maxillofacial Surg., Tokyo Med. & Den. Univ., ³Inst. of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Res. Foundation, ⁴New Industry Creation Hatchery Ctr., Tohoku Univ.

Oral Sessions

Cancer, Chemotherapy, Antibody Therapy (3)

2-O-D2-116:3016:42 CDK8 maintains stemness and tumorigenicity of glioma stem cells by controlling the c-MYC pathway Kazuya Fukasawa, Kazuya Tokumura, Sayuki Iwahashi, Takashi Iezaki, Eiichi Hinoi Lab. Pharmacol., Dept. Bioactive Molecules, Gifu Pharmaceutical Univ.

2-O-D2-216:4216:54 Biological significance of CYLD expression in malignant characteristics of glioblastoma multiforme. Yuki Ito¹, Michiko Yamaoka¹, Yuki Shirakawa¹, Takuichiro Hide², Hideyuki Saito^1,3, Hirofumi Jono^1,3 ¹Pharm., ²Neurosurg., ³Pharm.

2-O-D2-316:5417:06 Angiotensin II promotes tumor growth and metastatic lesion formation of murine TNBC 4T1 cells through the fibroblasts around cancer cells Tomohiro Takiguchi^1,2, Fumi Takahashi², Shin Ishikane², Toshiyuki Sasaguri¹ ¹Dept. Clin. Pharmacol., Fac. Med. Sci., Kyushu Univ., ²Dept. Pharmacol., Sch. Med., Univ. Occup. & Environ. Health, Japan

2-O-D2-417:0617:18 Aberrant (pro)renin receptor expression induces genomic instability in pancreatic ductal adenocarcinoma through upregulation of SMARCA5/SNF2H Akira Nishiyama, Yuki Shibayama Department of Pharmacology, Kagawa University Medical School

Oral Sessions

Kidney, Urination (2), Hypertension (1)

2-O-D3-117:3017:42 Identification of a candidate drug for the prevention of cisplatin-induced nephrotoxicity by a database analysis-basic research-clinical study Yasumasa Ikeda¹, Hirofumi Hamano², Mitsuhiro Goda², Keijo Fukushima³, Seiji Kishi⁴, Masayuki Chuma⁵, Yoshito Zamami⁶, Licht Miyamoto⁷, Keisuke Ishizawa⁶, Hiromichi Fujino³, Ken-ichi Aihara⁸, Koichiro Tsuchiya⁷, Toshiaki Tamaki⁹ ¹Dept. Pharmacol. Tokushima Univ., ²Dept. Pharm. Tokushima Univ. Hosp., ³Dept. Pharmacol. Life Sci., ⁴Dept. General Med. Kawasaki Med. Hosp., ⁵Clin. Trial Ctr. Tokushima Univ. Hosp., ⁶Dept. Clin. Pharmacol. Tokushima Univ., ⁷Dept. Med. Pharmacol. Tokushima Univ., ⁸Dept. Comm. Med. and Med. Sci., ⁹Anan Med. Ctr.

2-O-D3-217:4217:54 Streptolysin O: a novel mediator of endothelial dysfunction Masashi Mukohda¹, Mihiro Seki¹, Sho Nakamura², Kosuke Takeya³, Akira Takanori⁴, Takanori Yano⁵, Risuke Mizuno¹, Hiroshi Ozaki¹ ¹Lab. of Vet. Pharm., Faculty of Vet. Med., Okayama Univ. of Science, ²Lab. of Animal Health, Faculty of Vet. Med., Okayama Univ. of Science, ³Lab. of Biochem., Faculty of Vet. Med., Okayama Univ. of Science, ⁴Lab. of Vet Internal Med, Faculty of Vet. Med., Okayama Univ. of Science, ⁵Dept. of biochem., Faculty of Science, Okayama Univ. of Science

2-O-D3-317:5418:06 Effects of molidustat, a HIF-PHD inhibitor, on sodium dynamics and distribution in hypertensive subtotally nephrectomized rats Anqi Zhang, Daisuke Nakano, Norihiko Morisawa, Akira Nishiyama Dept. Pharmacol., Kagawa Univ.

2-O-D3-418:0618:18 Dexamethasone induces sodium and water loss in skin Kento Kitada¹, Norihiko Morisawa², Daisuke Nakano¹, Jens Titze³, Akira Nishiyama¹ ¹Department of Pharmacology, Faculty of Medicine, Kagawa University, ²Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, ³Cardiovascular and Metabolic Disorders, Duke-NUS Medical School

2-O-D3-518:1818:30 Development of a novel treatment for interstitial cystitis using filtered adipose-derived stem cells lysate Maaya Shibayama¹, Yuji Hotta¹, Kotomi Maeda¹, Seiji Matsumoto², Tomoya Kataoka³, Tokunori Yamamoto⁴, Kazunori Kimura^1,3 ¹Dept. Hospital Pharm., Grad. Sch. Pharm. Sci., Nagoya City Univ., ²Cent. Adv. Res. Edu., Asahikawa Med. Univ., ³Dept. Clinical Pharm., Grad. Sch. Med. Sci., Nagoya City Univ., ⁴Dept. Neph., Grad. Sch. Med. Sci., Nagoya Univ.